Tag : RELAPSING MULTIPLE SCLEROSIS

  • Early and continuous ofatumumab treatment offers durable outcomes over 7 years in pwRMS

    Ofatumumab, a fully human anti-CD20 monoclonal antibody, previously demonstrated superior efficacy versus teriflunomide in the phase 3 ASCLEPIOS I/II trials in people with relapsing multiple sclerosis (PwRMS). Earlier data had shown that ofatumumab maintained a favorable safety profile and sustained efficacy over 6 years of treatment. At the AAN Annual Meeting 2025, Dr. Gabriel Pardo from the Oklahoma Medical Research Foundation presented updated findings on the long-term safety and disability outcomes associated with continuous ofatumumab treatment for up to 7 years. The analysis also explored the impact of early versus delayed ofatumumab initiation, including outcomes in recently diagnosed (≤3 years) and treatment-naïve (RDTN) patients.

  • CONFERENCE UPDATE
    Long-term efficacy and safety of ofatumumab treatment for up to 6 years demonstrated in patients with RMS

    Ofatumumab is a fully human monoclonal antibody (mAb) against CD20. Monthly subcutaneous injections of ofatumumab 20mg have previously been approved for the treatment of relapsing multiple sclerosis (RMS) in adult patients. Previously in the phase 3 ASCLEPIOS I/II trials, ofatumumab led to a greater reduction of the clinical and magnetic resonance imaging (MRI) disease activity in people with RMS (pwRMS) up to 30 months compared with teriflunomide. Additionally, results from the open-label extension (OLE) study, ALITHIOS, substantiated the sustained efficacy of ofatumumab in pwRMS for up to 5 years. In the captioned analysis, the longer-term safety and efficacy of ofatumumab treatment for up to 6 years in pwRMS were evaluated to further elucidate the benefit-risk profile of ofatumumab in pwRMS.